Description
+ Include: 96 videos + 1 pdf, size: 18.2 GB
+ Target Audience: oncologist, hematologist
+ Sample video: contact me for sample video
+ Information:
The Society of Hematologic Oncology (SOHO) Eleventh Annual Meeting 2023 took place from September 6-9, 2023, at the George R. Brown Convention Center in Houston, Texas. This hybrid event offered both in-person and virtual attendance options. The meeting focused on the latest advances and practical clinical applications in the field of hematologic malignancies. Key features of the program included:
- General sessions
- Meet-the-Professor sessions
- Plenary lectures
- Expert sessions
- Oral abstract presentations
- Interactive and informal exchanges
Topics covered included the latest advances in the pathophysiology and therapy of leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, and developments in cellular therapy
These sessions were designed to cater to a wide range of professionals involved in hematologic oncology, providing them with the latest knowledge and tools to improve patient outcomes.
+ Topics:
Plenary Session 1 Acute Lymphoblastic Leukemia.mp4
Plenary Session 2 Chronic Myeloid Leukemia.mp4
Plenary Session 3 Emerging BCL 2 Inhibitors.mp4
Session 1 Acute Lymphoblastic Leukemia Acute Leukemia of Ambiguous Lineage.mp4
Session 1 Acute Lymphoblastic Leukemia Approach to Ph-Like ALL.mp4
Session 1 Acute Lymphoblastic Leukemia CNS Prophylaxis in ALL.mp4
Session 1 Acute Lymphoblastic Leukemia Menin Inhibition for KMT2A Rearranged ALL.mp4
Session 1 Acute Lymphoblastic Leukemia Oral Abstract ALL-300 First Report of PhALLCON A Phase 3 Study Comparing Ponatinib Versus Imatinib.mp4
Session 1 Acute Lymphoblastic Leukemia Oral Abstract ALL-363 Comparison of Treatment Outcomes in Adolescents and Young Adults.mp4
Session 1 Acute Lymphoblastic Leukemia Ph+ ALL – Novel Therapies.mp4
Session 1 Acute Lymphoblastic Leukemia Role of Transplant in the Era of CAR T Cells.mp4
Session 1 Acute Lymphoblastic Leukemia Sequencing Immunotherapies in Adults With ALL.mp4
Session 2 Myelodysplastic Neoplasms Oral Abstract MDS-044 Cancer Disparities in Survival of Patients With Hematologic Malignancies.mp4
Session 2 Myelodysplastic Neoplasms Oral Abstract MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia.mp4
Session 2 Myelodysplastic Neoplasms Update on CHIP and CCUS.mp4
Session 2 Myelodysplastic Neoplasms Update on Classifications and Prognostic Models.mp4
Session 2 Myelodysplastic Neoplasms Update on the Biology of MDS.mp4
Session 2 Myelodysplastic Neoplasms Update on Treatment of Higher Risk MDS.mp4
Session 2 Myelodysplastic Neoplasms Update on Treatment of Lower Risk MDS.mp4
Session 3 Acute Myeloid Leukemia DEBATE Achieving Best Response Is Desirable Prior to Allogeneic Stem Cell Transplant.mp4
Session 3 Acute Myeloid Leukemia DEBATE Prior Therapy Is Not Needed for Transplanting Patients With Relapsed or Refractory AML.mp4
Session 3 Acute Myeloid Leukemia Familial Predisposition to AML Prevalence and Implications for Management.mp4
Session 3 Acute Myeloid Leukemia Is Acute Myeloid Leukemia with Monocytic Features a Separate Entity.mp4
Session 3 Acute Myeloid Leukemia Oral Abstract AML-112 Impact of Consolidation Chemotherapy Intensity.mp4
Session 3 Acute Myeloid Leukemia Post-Transplant Maintenance Therapy.mp4
Session 3 Acute Myeloid Leukemia Triplet Regimens in AML; Beyond Azacytidine Plus Venetoclax.mp4
Session 3 Acute Myeloid Leukemia What Is the Future of Menin Inhibitors in AML.mp4
Session 3 Acute Myeloid Leukemia What Is the Role of Quizartinib in the Current Landscape of AML Therapy.mp4
Session 4 Chronic Myeloid Leukemia Cost Benefit Role of TKI Choice.mp4
Session 4 Chronic Myeloid Leukemia Epigenetic Dysregulation of CML.mp4
Session 4 Chronic Myeloid Leukemia Genomic Complexity Beyond BCR ABL1 and Its Clinical Impact.mp4
Session 4 Chronic Myeloid Leukemia Oral Abstract CML-310 Early Cytogenetic or Molecular Landmark.mp4
Session 4 Chronic Myeloid Leukemia Rational Choice of TKI.mp4
Session 4 Chronic Myeloid Leukemia The New ELN Molecular Recommendations.mp4
Session 5 Myeloproliferative Neoplasms Addressing Anemia in Myelofibrosis.mp4
Session 5 Myeloproliferative Neoplasms Choosing and Properly Using a JAK Inhibitor in Myelofibrosis.mp4
Session 5 Myeloproliferative Neoplasms Managing Accelerated and Blast Phase MPN.mp4
Session 5 Myeloproliferative Neoplasms Modern Prognostication in Classic MPNs.mp4
Session 5 Myeloproliferative Neoplasms Novel Non-JAK Inhibitor Therapies for Myelofibrosis.mp4
Session 5 Myeloproliferative Neoplasms Oral Abstract MPN-470 Examining Racial Disparities in Primary Myelofibrosis.mp4
Session 6 Multiple Myeloma BCMA GPRC5D FcRH5 CARs BsAbs How to Choose.mp4
Session 6 Multiple Myeloma CAR BsAb Toxicity Prevention, Treatment and Surveillance.mp4
Session 6 Multiple Myeloma DEBATE Smoldering MM Time to Treat Personalized.mp4
Session 6 Multiple Myeloma DEBATE Smoldering MM Time to Watch and Wait.mp4
Session 6 Multiple Myeloma Frontline Treatment for High-Risk Personalized.mp4
Session 6 Multiple Myeloma Next Generation Therapeutics Degraders and Targeted Therapy Where Will They Fit Personalized Therapy in MM.mp4
Session 6 Multiple Myeloma Oral Abstract MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma.mp4
Session 6 Multiple Myeloma Treatment of Frail MM Patients Personalized Care.mp4
Session 7 Chronic Lymphocytic Leukemia Clinical Significance of MBL.mp4
Session 7 Chronic Lymphocytic Leukemia DEBATE Stop vs Continue VenG MRD+ at 1 Year of VenG Stop Therapy and Continue VenG.mp4
Session 7 Chronic Lymphocytic Leukemia How Biologic Markers Impact Outcomes With Novel Therapy.mp4
Session 7 Chronic Lymphocytic Leukemia How We Developed a Curative Therapy for CLL and Stopped Using It.mp4
Session 7 Chronic Lymphocytic Leukemia Is FD Therapy the New SOC in FL CLL.mp4
Session 7 Chronic Lymphocytic Leukemia Oral Abstract CLL-094 Lisocabtagene Maraleucel (liso-cel) in RR Chronic Lymphocytic Leukemia.mp4
Session 8 T-Cell Lymphoma A Multidisciplinary Approach to the Management of Mycosis Fungoides.mp4
Session 8 T-Cell Lymphoma Managing Rare T-Cell Lymphoma Subtypes.mp4
Session 8 T-Cell Lymphoma New Insights Into the Pathogenesis of T-Cell Lymphoma and How This May Guide Treatment.mp4
Session 8 T-Cell Lymphoma Novel Targeted Agents in T-Cell Lymphoma.mp4
Session 8 T-Cell Lymphoma Tailoring Therapy in PTCL.mp4
Session 9 Indolent B-Cell Lymphoma Bispecific Antibodies or CAR T-Cells for Indolent NHL.mp4
Session 9 Indolent B-Cell Lymphoma Novel Combinations in Indolent Lymphoma.mp4
Session 9 Indolent B-Cell Lymphoma Oral Abstract IBCL-098 TRANSCEND FL Phase II Study Results of Lisocabtagene.mp4
Session 9 Indolent B-Cell Lymphoma Treatment of Follicular Lymphoma, What Is the New Order.mp4
Session 9 Indolent B-Cell Lymphoma Treatment Options for Marginal Zone Lymphoma.mp4
Session 10 Aggressive B-Cell Lymphoma Incorporating Novel Agents in Frontline DLBCL.mp4
Session 10 Aggressive B-Cell Lymphoma Optimizing the Use of Novel Agents in Relapsed Refractory DLBCL.mp4
Session 10 Aggressive B-Cell Lymphoma Oral Abstract ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab.mp4
Session 10 Aggressive B-Cell Lymphoma The Emergence of Bispecific Antibodies in Aggressive B-Cell Lymphoma.mp4
Session 10 Aggressive B-Cell Lymphoma The New Algorithm for Second-Line LBCL.mp4
Session 10 Aggressive B-Cell Lymphoma The Treatment of Primary and Secondary CNS Lymphoma.mp4
Session 10 Aggressive B-Cell Lymphoma Treatment Options for Primary Mediastinal B-Cell Lymphoma.mp4
Session 11 Mantle Cell Lymphoma CAR T-Cell Therapy and Bispecific Antibodies in Mantle Cell Lymphoma.mp4
Session 11 Mantle Cell Lymphoma Emerging Novel Agents in Mantle Cell Lymphoma.mp4
Session 11 Mantle Cell Lymphoma Is Stem Cell Transplantation Still Necessary in Frontline Mantle Cell Lymphoma.mp4
Session 11 Mantle Cell Lymphoma What is High Risk Mantle Cell Lymphoma and How Should We Treat It.mp4
Session 12 Hodgkin Lymphoma Oral Abstract HL-642 Does Interim PET Assessment After Two Cycles of Treatment.mp4
Session 12 Hodgkin Lymphoma Risk-Based Treatment of Hodgkin Lymphoma in the Era of Novel Therapies.mp4
Session 12 Hodgkin Lymphoma Treatment of HL in Older Patients.mp4
Session 13 Cellular Therapy DEBATE Early HCT in Myeloma.mp4
Session 13 Cellular Therapy DEBATE Late HCT in Myeloma.mp4
Session 13 Cellular Therapy DEBATE Should Patients with AML and Active Disease be Transplanted Con.mp4
Session 13 Cellular Therapy DEBATE Should Patients with AML and Active Disease be Transplanted Pro.mp4
Session 13 Cellular Therapy Oral Abstract CT-186 Impact of Allogeneic Hematopoietic Cell Transplantation.mp4
Session 14 Next Questions Acute Lymphoblastic Leukemia.mp4
Session 14 Next Questions Acute Myeloid Leukemia.mp4
Session 14 Next Questions Aggressive B-Cell Lymphoma.mp4
Session 14 Next Questions Cellular Therapy.mp4
Session 14 Next Questions Chronic Lymphocytic Leukemia.mp4
Session 14 Next Questions Chronic Myeloid Leukemia.mp4
Session 14 Next Questions Hodgkin Lymphoma.mp4
Session 14 Next Questions Indolent B-Cell Lymphoma.mp4
Session 14 Next Questions Mantle Cell Lymphoma.mp4
Session 14 Next Questions Multiple Myeloma.mp4
Session 14 Next Questions Myelodysplastic Syndromes.mp4
Session 14 Next Questions Myeloproliferative Neoplasms.mp4
Session 14 Next Questions T-Cell Lymphoma.mp4
SOHO2023-Program.pdf
Reviews
There are no reviews yet.